Search

Displaying results 7721 - 7730 of 10000 in total
  1. Drug

    Platelet Lysate

    go.drugbank.com/drugs/DB15869
    Investigational

    [A220188] It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.

  2. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    [A220348] In a head-to-head trial, the former tracer detected twice as many lesions as the latter.[A220348] … [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.

  3. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta]. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]

    Synonyms: alpha-D-galactosidase, alpha-galactosidase AProducts: REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML
  4. Drug

    Piroxicam cinnamate

    go.drugbank.com/drugs/DB15883
    Investigational

    Categories: Heterocyclic Compounds, 1-RingProducts: SINARTROL INFIAMMAZIONE E DOLORE
  5. Drug

    Methacetin methoxy-C-13

    go.drugbank.com/drugs/DB15885
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: p-Acetanisidine C-13, 13-C-methacetin
  6. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  7. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    As of August, 2020 the candidate is in Phase II clinical trials[A219758]. … Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system[L16503]

  8. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), [Odesivimab] (REGN 3471), and [Atoltivimab] (REGN 3470) in equimolar proportions

  9. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens. … Chlormadinone acetate is a progesterone derivative first synthesized in 1961.

    Mixtures: LUTORAL-E
  10. Drug

    Escin

    go.drugbank.com/drugs/DB15907
    Investigational

    Sodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and